Autres langues Solid Biosciences Inc.

Actions

SLDB

US83422E2046

Temps réel estimé Cboe BZX Autres places de cotation 16:33:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
9,03 ^USD	+2,73 %		-2,41 %	+44,79 %

01/04	Le SGT-003 de Solid Biosciences reçoit le label de maladie pédiatrique rare de la FDA américaine	MT
01/04	Solid Biosciences Inc. reçoit la désignation de maladie pédiatrique rare de la FDA pour le candidat de thérapie génique SGT-003 contre la dystrophie musculaire de Duchenne	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03/04
Solid Biosciences' SGT-003 Receives US FDA's Rare Pediatric Disease Label	01/04
Solid Biosciences Gets FDA Rare-Pediatric Designation for SGT-003 in Duchenne	01/04
Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01/04
Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	01/04
Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium	27/03
North American Morning Briefing : Inflation -2-	15/03
Solid Biosciences Provides Fourth Quarter and Full-Year 2023 Business Update and Financial Results	13/03
Solid Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD	07/03
Solid Biosciences Inc. Announces Licensing Agreement with Armatus Bio for the Use of Aav-Slb101, A Proprietary, Muscle-Targeted Capsid, in the Development of an Rnai Therapy to Treat Fshd	07/03
Solid Biosciences to Participate at Upcoming Investor Conferences	06/03
Solid Biosciences Gets FDA Orphan Drug Designation for Duchenne Drug Candidate	16/01
Solid Biosciences Gets Orphan Drug Designation for SGT-003	16/01
Solid Biosciences Granted FDA Orphan Drug Designation for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003	16/01
Top Midday Gainers	09/01
Solid Biosciences Shares Surge After Revealing $109 Million Private Placement	09/01
Solid Biosciences Announces $109 Million Private Placement	08/01
Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors	08/01
Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference	04/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Solid Biosciences Inc.

Actions

SLDB

US83422E2046

Autres langues

Filtres